Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow grows to $108.12M
Q1 FY2026 financing cash flow was $108.12M, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $173.2M. Over 3 fiscal years it compounded at -4.7% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $108.12M or moves back toward the trailing-twelve-month quarterly average of $43.3M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 65.09M USD
- Year-over-year change
- -59.8%
- 4-year CAGR
- +34.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 65.09M | -59.8% |
| FY2024 | 2024-12-31 | 161.88M | +539510.0% |
| FY2023 | 2023-12-31 | 30K | -100.0% |
| FY2022 | 2022-12-31 | 75.26M | +278.5% |
| FY2021 | 2021-12-31 | 19.89M | — |
Financing Cash Flow vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +64727.2% is the 2nd highest of 11, against a peer median of +301.5%.
- Over three fiscal years its annual growth of -4.7% compares with a peer median of +33.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $365.04M USD | +52499.0% | +12.5% | — | |
| LTM Mar 2026 | $251.49M USD | +466.1% | +53.9% | 698594.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $219.24M USD | +164739.1% | +946.8% | — |
| LTM Mar 2026 | $173.2M USD | +64727.2% | -4.7% | — | |
| LTM Mar 2026 | $165.89M USD | +1517.0% | +11.1% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $143.06M USD | +136.8% | -62.1% | — |
| LTM Mar 2026 | $141.69M USD | +10.0% | -4.0% | — | |
| LTM Mar 2026 | $141.48M USD | +10580.1% | +128.2% | — | |
| LTM Mar 2026 | $88.73M USD | +27.9% | +236.4% | 2309.3% | |
| LTM Mar 2026 | $2.59M USD | +127.8% | +75.3% | 1.2% | |
| LTM Dec 2025 | CHF 1.02M CHF | -9.0% | -10.2% | 28.5% | |
| Peer median (excluding LRMR) | — | +301.5% | +33.2% | 1168.9% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | (1.35M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.47M | 6.62M | 7.62M | 8.8M | 7M |
| Change in Working Capital | 2.75M | 1.67M | (2.51M) | 6.18M | 47.1M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (974K) | 26K | (403K) | 1.14M | 2.79M |
| Other Working Capital | 3.72M | 1.64M | (2.11M) | 5.03M | 44.31M |
| Other Non-Cash Items | (15K) | (820K) | (1.93M) | (5.45M) | (281K) |
| Operating Cash Flow | (42.11M) | (27.57M) | (33.46M) | (70.76M) | (113.2M) |
| Capital Expenditures | (333K) | (100K) | (164K) | (515K) | (91K) |
| Acquisitions (Net) | (24.5K) | 90.86K | 0 | 0 | 0 |
| Purchases of Investments | (8.25M) | (133.61M) | (101.23M) | (227.87M) | (83.6M) |
| Sales of Investments | 32.75M | 42.75M | 134.75M | 143M | 184M |
| Other Investing Activities | 24.5K | (90.86K) | 0 | 0 | 0 |
| Investing Cash Flow | 24.17M | (90.96M) | 33.35M | (85.39M) | 100.31M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 19.89M | 75.26M | 30K | 161.81M | 65.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 77K | 0 |
| Financing Cash Flow | 19.89M | 75.26M | 30K | 161.88M | 65.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.95M | (43.27M) | (76K) | 5.74M | 52.19M |
| Free Cash Flow | (42.44M) | (27.67M) | (33.62M) | (71.28M) | (113.29M) |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.